Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000616774
Ethics application status
Approved
Date submitted
15/05/2013
Date registered
29/05/2013
Date last updated
28/06/2021
Date data sharing statement initially provided
11/02/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Randomised trial of treatment for tennis elbow comparing the effects of different injection treatments on pain reduction
Scientific title
Comparative effectiveness of ultrasound-guided injection with either autologous platelet rich plasma or glucocorticoid for ultrasound-proven lateral epicondylitis: a three-arm randomised placebo-controlled trial
Secondary ID [1] 281833 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
lateral epicondylitis 288189 0
Condition category
Condition code
Musculoskeletal 288553 288553 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
1) single ultrasound guided injection of autologous platelet rich plasma (2ml) into the site of maximal abnormality in the elbow.

To obtain the autologous platelet rich plasma, 5 ml of venesected blood will be centrifuged for 7 minutes at 1500 revs/sec and then the buffy coating and 2ml of the supernatant will be aspirated using a 22 gauge needle into a 3ml syringe. This 2ml will then be injected into the elbow.

2) single ultrasound guided injection of glucocorticoid (Celestone Chronodose 1ml + 1 ml normal saline) into the site of maximal abnormality in the elbow
Intervention code [1] 286391 0
Treatment: Drugs
Intervention code [2] 287254 0
Treatment: Other
Comparator / control treatment
1) single ultrasound guided injection of saline (2ml) into the site of maximal abnormality in the elbow
Control group
Placebo

Outcomes
Primary outcome [1] 288713 0
Participant's global assessment of overall pain, pain at night and activity-related pain will be measured with a standardized 0-10 numerical scale comprising a vertical scale labelled ’no pain‘ at the bottom (0) and ’maximal imaginable pain‘ at the top (10)
Timepoint [1] 288713 0
Baseline, 3, 6, 12, 24, 52 weeks
Primary outcome [2] 288714 0
Patient-rated Tennis Elbow Evaluation (PRTEE) questionnaire
Timepoint [2] 288714 0
Baseline, 3, 6, 12, 24 and 52 weeks
Secondary outcome [1] 300803 0
Assessment of Quality of Life (AQoL) questionnaire
Timepoint [1] 300803 0
Baseline, 3, 6, 12, 24 and 52 weeks
Secondary outcome [2] 300804 0
Pain-free grip force will be measured with a digital grip dynamometer.
Timepoint [2] 300804 0
Baseline, 12 and 52 weeks
Secondary outcome [3] 300805 0
Direct and indirect health care costs will be calculated using a modified "cost and consequences questionnaire" specifically targeted towards elbow pain.
Timepoint [3] 300805 0
Weekly intervals for the first 12 weeks and every 4 weeks thereafter for a total of 52 weeks
Secondary outcome [4] 300806 0
Perceived recovery: Participants will rate their perceived recovery on a 5- point ordinal scale (‘much worse’ to ‘much improved and/or completely recovered’).
Timepoint [4] 300806 0
3, 6, 12, 24 and 52 weeks
Secondary outcome [5] 300807 0
Adverse effects (such as worsening of pain or discomfort at injection site) will be reported by an open-ended question
Timepoint [5] 300807 0
3, 6, 12, 24 and 52 weeks
Secondary outcome [6] 302799 0
Success of blinding: Participants will be asked to indicate which treatment they believe they received
Timepoint [6] 302799 0
12 and 52 weeks
Secondary outcome [7] 302800 0
Use of online vs. paper questionnaire completion
Timepoint [7] 302800 0
52 weeks
Secondary outcome [8] 320130 0
Participant's global assessment of overall pain, pain at night and activity-related pain will be measured with a standardized 0-10 numerical scale comprising a vertical scale labelled ’no pain‘ at the bottom (0) and ’maximal imaginable pain‘ at the top (10). This is a composite secondary outcome
Timepoint [8] 320130 0
measured weekly for first 12 weeks, then every 4 weeks up to 52 weeks

Eligibility
Key inclusion criteria
1) lateral elbow pain > or = six weeks duration
2) reproducibility of pain by two or more of the following tests: palpation of the lateral epicondyle and/or the common extensor origin of the elbow, gripping, resisted wrist or second or third finger extension (dorsiflexion)
3) ultrasound-confirmed lesion
4) ability to read and write in English
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1) bilateral symptoms of lateral elbow pain
2) any other elbow pathology
3) generalised inflammatory arthritis such as rheumatoid arthritis
4) concurrent shoulder and/or neck pain and/or pain proximal to the elbow on the affected side
5) any wound or skin lesion on the lateral side of the affected elbow
6) neurological symptoms or signs in the affected arm
7) severe infection
8) known malignancy
9) bleeding disorder
10) previous surgery to the elbow
11) local glucocorticoid injection in the previous six months
12) oral glucocorticoids in the previous three months
13) large tear > or = 15mm in the common extensor origin
or a torn lateral collateral ligament
14) lack of informed consent
15) any other reason thought likely to result in inability to complete the trial

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be recruited via online and printed advertisements and from medical practitioners. Respondents will undergo an initial screening to ensure inclusion. Those who are eligible at this point will be given the participant information and consent form and will be invited to participate provided ultrasound criteria are met. Following written consent and diagnostic ultrasonography, participants will be randomly assigned in random permuted blocks of differing sizes to receive one of the three treatment regimens, stratified by radiologist and size of the tear (< or > or = 6mm). The randomisation sequence will be created using a computer-generated table of random numbers. To conceal randomisation, stratified allocations will be sealed in consecutively numbered opaque envelopes and kept in a locked location accessible only by an independent administrator. This administrator (not involved in the trial in any other capacity except for opening randomisation envelopes and preparing syringes with treatments) will open the next envelope in sequence at each site and prepare syringes accordingly.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation schedule
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/06/2013
Actual
5/06/2013
Date of last participant enrolment
Anticipated
Actual
10/10/2018
Date of last data collection
Anticipated
Actual
31/10/2019
Sample size
Target
180
Accrual to date
Final
151
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 5117 0
The Queen Elizabeth Hospital - Woodville
Recruitment hospital [2] 7358 0
Royal Prince Alfred Hospital - Camperdown
Recruitment postcode(s) [1] 15152 0
2050 - Camperdown

Funding & Sponsors
Funding source category [1] 286617 0
Government body
Name [1] 286617 0
National Health and Medical Research Council
Country [1] 286617 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Monash University
Wellington Rd
Clayton VIC
Australia
Country
Australia
Secondary sponsor category [1] 285403 0
None
Name [1] 285403 0
Address [1] 285403 0
Country [1] 285403 0
Other collaborator category [1] 277264 0
Individual
Name [1] 277264 0
Professor Anthony Harris
Address [1] 277264 0
Monash University Centre for Health Economics
Clayton Campus, Wellington Rd
Victoria 3800
Country [1] 277264 0
Australia
Other collaborator category [2] 277294 0
Individual
Name [2] 277294 0
Ms Alexandra Gorelik
Address [2] 277294 0
Monash Department of Clinical Epidemiology, Cabrini Hospital
Cabrini Medical Centre
183 Wattletree Rd
Malvern
Victoria, 3144
Country [2] 277294 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288690 0
Cabrini Human Research Ethics Committee
Ethics committee address [1] 288690 0
Ethics committee country [1] 288690 0
Australia
Date submitted for ethics approval [1] 288690 0
Approval date [1] 288690 0
25/02/2013
Ethics approval number [1] 288690 0
05-04-02-13
Ethics committee name [2] 289268 0
Monash University Human Research Ethics Committee (MUHREC)
Ethics committee address [2] 289268 0
Ethics committee country [2] 289268 0
Australia
Date submitted for ethics approval [2] 289268 0
Approval date [2] 289268 0
19/03/2013
Ethics approval number [2] 289268 0
CF13/765-2013000342
Ethics committee name [3] 294233 0
Sydney Local Health District (RPAH Zone)
Ethics committee address [3] 294233 0
Ethics committee country [3] 294233 0
Australia
Date submitted for ethics approval [3] 294233 0
11/11/2013
Approval date [3] 294233 0
17/02/2014
Ethics approval number [3] 294233 0
Protocol No X13-0401 & HREC/13/RPAH/556
Ethics committee name [4] 294234 0
CALHN Research Office
Ethics committee address [4] 294234 0
Ethics committee country [4] 294234 0
Australia
Date submitted for ethics approval [4] 294234 0
19/03/2015
Approval date [4] 294234 0
26/11/2015
Ethics approval number [4] 294234 0
SSA/15/TQEH/165

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 37318 0
Prof Rachelle Buchbinder
Address 37318 0
Suite 41, Cabrini Medical Centre
183 Wattletree Rd, Malvern, VIC 3144
Country 37318 0
Australia
Phone 37318 0
(613) 9508 1652
Fax 37318 0
Email 37318 0
[email protected]
Contact person for public queries
Name 37319 0
Allison Bourne
Address 37319 0
Suite 41, Cabrini Medical Centre
183 Wattletree Rd, Malvern, VIC 3144
Country 37319 0
Australia
Phone 37319 0
+61 395083499
Fax 37319 0
Email 37319 0
[email protected]
Contact person for scientific queries
Name 37320 0
Rachelle Buchbinder
Address 37320 0
Suite 41, Cabrini Medical Centre
183 Wattletree Rd, Malvern, VIC 3144
Country 37320 0
Australia
Phone 37320 0
+61 395083499
Fax 37320 0
Email 37320 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Individual participant data that underlie the results of articles after de-identification (text, tables, figures and appendices)
When will data be available (start and end dates)?
Beginning 9 months and ending 36 months following article publication
Available to whom?
Researchers who provide a methodologically sound proposal
Available for what types of analyses?
To achieve aims in the approved proposal
How or where can data be obtained?
Proposals should be directed to [email protected]


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseAutologous blood and platelet-rich plasma injection therapy for lateral elbow pain.2021https://dx.doi.org/10.1002/14651858.CD010951.pub2
N.B. These documents automatically identified may not have been verified by the study sponsor.